Randomised double-blind placebo controlled trial of treatment with pioglitazone in non-alcoholic steatohepatitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10319160

Enrollment

Registered

2003-09-12

Start date

2002-11-25

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System: Liver Digestive System Liver

Interventions

Pioglitazone vs placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Added 27/03/08: 1. Age 18-70 years 2. Histological evidence of NASH

Exclusion criteria

Exclusion criteria: Added 27/03/08: 1. Alcohol consumption >21units in males and >14 units in females 2. Diabetes Mellitus 3. Consumption of drugs that cause fatty liver 4. Other liver diseases (clinical or on liver biopsy)

Design outcomes

Primary

Measure	Time frame
Necro-inflammation and fibrosis score on liver biopsy.	—

Secondary

Measure	Time frame
1. Liver enzymes 2. Clinical and biochemical parameters of metabolic syndrome	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026